Thu, Jul 24, 2014, 3:30 AM EDT - U.S. Markets open in 6 hrs.

Recent

% | $
Click the to save as a favorite.

Zalicus Inc. Message Board

  • iamstocklasar iamstocklasar Dec 15, 2012 9:02 AM Flag

    Novartis-Zalicus and Cancer

    The trials are out there. They are buried. Its up to you to find them.

    CAMBRIDGE, Mass. -- October 19, 2010

    Zalicus Inc. (NASDAQ: ZLCS) presented data today on its research regarding
    novel synergistic drug combinations for the treatment of cancer at the
    ASCO-NCI-EORTC Molecular Markers meeting in Hollywood, FL on October 19, 2010.
    The poster entitled “Systematic Combination Screening Exploits Tumor Biology
    Networks to Create Context-specific Cytotoxicity”, Short, et.al, explores
    the association of cancer cell line genotype to combination drug
    sensitivity as a predictor of synergy and potentially responsive patient
    populations.

    Dr. Short and the Zalicus research team confirmed that broad synergy
    profiling, as opposed to single-agent response data, is required to maximally
    exploit drug synergy. Specifically, the team has demonstrated that temporal
    sequencing of drug combinations can yield greater synergy and overcome
    resistant phenotypes thereby increasing the probability of context-specific
    cytotoxicity. Importantly, this work establishes that correlating
    chemo-sensitivity and genomic determinants can be leveraged to identify
    potentially responsive patient populations.

    “These data, which were generated with our combination high-throughput
    screening (cHTS™) technology, are in alignment with the goals of our Novartis
    oncology collaboration whereby we can begin to associate drug sensitivity to
    genotype and in so doing, identify patient populations that may benefit from
    any given combination therapy,” commented Mark H.N. Corrigan, M.D., President
    and CEO of Zalicus Inc.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • bump

    • Bump....

    • Just a few that have recently been updated and are fairly new since the collaboration started. Looks like the Novartis partnership is alive and well. Too many to list here. The list goes on and on......

      Just look at clinical trials(dot)gov and you will find a boat load of combination drug trials for cancer and there genotypes. This certainly lines up to what Mr. Corrigan referred to at the ASCO-NCI-EORTC Molecular Markers meeting.

      Not yet open to enrollment-
      6/2012- A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER

      Currently recruiting-
      4/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors

      10/2010- A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

      5/2012- A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer

      9/2011-An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

      6/2010-A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.

      5/2012-A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer

      Sentiment: Strong Buy

      • 6 Replies to iamstocklasar
      • bumpy

      • Great info.

        Sentiment: Strong Buy

      • I definitely see alot here. We are back on our way UP!

      • Great information! Thanks!

        ZALICUS is a STRONG BUY!

        Sentiment: Strong Buy

      • It all began here. The entire Novartis compound library opened and entered into Zalicus's proprietary ULTRA Combination screening software. It became "Ultra" when the cancer genotypes were added to the assay models. An AMAZING partnership between these two firms.

        MARK THIS POST- The lid will blow on this stock when the investment community decides to value this partnership.

      • Man what a pipeline for combination drug trials, the list goes on an on.....

        quite a few have results in the first half of 2013-

        10/2012-A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer

        10/2012-An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer4/2012- Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

        5/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors

        1/2012- A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy

        4/2012- A Randomized, Double-blind, Placebo Controlled, Phase II Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation

        5/2011- A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

 
ZLCS
1.180.00(0.00%)Jul 15 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT